The multikinase inhibitors dasatinib, imatinib, nilotinib, bafetinib, ponatinib, MGCD516 (sitravatinib) and LCB 03-0110 have been shown to inhibit both DDR1 and DDR2 kinase activity and are mainly applied in the treatment of chronic myeloid leukaemia (CML), lung adenocarcinoma, and colorectal cancer, among other cancer types (86–91). Here, DDR1 is linked to cancer.